David Calkins

1 month ago | crstodayeurope.com | Eric D. Donnenfeld |Michele Corry |David Calkins

Dry eye disease (DED) continues to frustrate surgeons and patients alike with its multifactorial nature and resistance to one-size-fits-all solutions. Although current therapies offer varying degrees of relief, a growing pipeline of investigational treatments is targeting the root causes of ocular surface disease. From addressing meibomian gland dysfunction (MGD) to advancing care for neurotrophic keratopathy (NK), these therapies could reshape the management of complex cases.

Jan 14, 2025 | crstoday.com | Eric D. Donnenfeld |Michele Corry |David Calkins

We noticed you’re blocking ads Thanks for visiting CRSToday. Our advertisers are important supporters of this site, and content cannot be accessed if ad-blocking software is activated. In order to avoid adverse performance issues with this site, please white list https://crstoday.com in your ad blocker then refresh this page. Need help? Click here for instructions.